Janux Therapeutics, Inc. (NASDAQ:JANX) CEO David Alan Campbell Sells 25,000 Shares of Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) CEO David Alan Campbell sold 25,000 shares of Janux Therapeutics stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $51.60, for a total value of $1,290,000.00. Following the completion of the sale, the chief executive officer now directly owns 257,054 shares of the company’s stock, valued at approximately $13,263,986.40. This trade represents a 8.86 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

David Alan Campbell also recently made the following trade(s):

• On Monday, October 28th, David Alan Campbell sold 25,000 shares of Janux Therapeutics stock. The shares were sold at an average price of $53.54, for a total transaction of $1,338,500.00.
• On Friday, September 27th, David Alan Campbell sold 25,000 shares of Janux Therapeutics stock. The shares were sold at an average price of $46.31, for a total transaction of $1,157,750.00.

Janux Therapeutics Stock Performance

NASDAQ JANX opened at $46.39 on Thursday. The company has a market capitalization of $2.43 billion, a P/E ratio of -39.65 and a beta of 3.52. Janux Therapeutics, Inc. has a 52-week low of $7.79 and a 52-week high of $65.60. The company has a fifty day moving average of $50.02 and a 200-day moving average of $45.82.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.18). The firm had revenue of $0.44 million for the quarter, compared to the consensus estimate of $1.50 million. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The firm’s quarterly revenue was down 82.6% compared to the same quarter last year. As a group, analysts forecast that Janux Therapeutics, Inc. will post -1.35 EPS for the current fiscal year.

Hedge Funds Weigh In On Janux Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in JANX. Summit Securities Group LLC bought a new stake in shares of Janux Therapeutics in the 2nd quarter valued at about $29,000. Amalgamated Bank increased its stake in Janux Therapeutics by 61.1% in the 2nd quarter. Amalgamated Bank now owns 970 shares of the company’s stock worth $41,000 after purchasing an additional 368 shares during the period. Plato Investment Management Ltd bought a new stake in Janux Therapeutics in the second quarter valued at approximately $42,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Janux Therapeutics by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock valued at $87,000 after purchasing an additional 339 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Janux Therapeutics in the second quarter worth approximately $151,000. Institutional investors own 75.39% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on JANX. Scotiabank cut their price target on Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating for the company in a report on Friday, August 9th. Leerink Partners started coverage on Janux Therapeutics in a research note on Friday, November 22nd. They issued an “outperform” rating and a $79.00 target price for the company. William Blair reiterated an “outperform” rating on shares of Janux Therapeutics in a research report on Thursday, November 14th. Cantor Fitzgerald restated an “overweight” rating and issued a $100.00 price objective on shares of Janux Therapeutics in a research report on Thursday, November 7th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $63.00 target price on shares of Janux Therapeutics in a report on Thursday, November 7th. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $67.70.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.